Issues - Gennaio 2025

Ho AY, Shiao S, Kobald SA, et al.

PEARL: a phase ib/ii biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer

J Clin Oncol 2024;42(36):4282-4293

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

Dennis N, Dunton K, Livings C, et al.

Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial

Eur J Cancer 2024; Volume 0, Issue 0, 115192. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

Mosher CE, Lee S, Addington EL, et al.

Randomized controlled trial of acceptance and commitment therapy for fatigue interference with functioning in metastatic breast cancer

J Clin Oncol 2024 Oct 25:JCO2400965. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

Oliveira M, Pominchuk D, Nowecki Z, et al.

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Lancet Oncol 2024;25(11):1424-1439

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

Montagna G, Laws A, Ferrucci M, et al.

Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05/ICARO study

J Clin Oncol 2024 Nov 7:JCO2401052. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

Turner NC, Im SA, Saura C, et al.

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

N Engl J Med 2024;391(17):1584-1596

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

Romanos-Nanclares A, Willett WC, Rosner B, et al.

Proinflammatory dietary pattern and risk of total and subtypes of breast cancer among U.S. women

J Natl Cancer Inst 2024 Nov 20:djae301. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract | Scarica ppt

Huppert LA, Wolf D, Yau C, et al.

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Ann Oncol 2024 Oct 28:S0923-7534(24)04070-5. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

de Azambuja E, Piccart-Gebhart M, et al.

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open 2024;9(11):103938

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

Molinelli C, Bruzzone M, Blondeaux E, et al.

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Eur J Cancer 2024 Nov 4;213:115113. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

Johnson HM, Song J, Warneke CL, et al.

Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy

Cancer 2024 Oct 29. Epub ahead of print

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

Brufsky A, Kwan ML, Sandin R, et al.

Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer

Breast Cancer Res Treat 2024;208(2):223-235

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

Zhang Q, Freeman JQ, Zhao F, et al.

Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry

J Clin Oncol Advances 2024:1

Simonpietro Marrocco Issues, Dicembre 2024

Leggi abstract

Breast Cancer Journal Scan

Autore: Simonpietro Marrocco

Home ⁄ Articles Posted by Simonpietro Marrocco (Page 2)

Issues - Gennaio 2025

PEARL: a phase ib/ii biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer

Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial

Randomized controlled trial of acceptance and commitment therapy for fatigue interference with functioning in metastatic breast cancer

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05/ICARO study

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Proinflammatory dietary pattern and risk of total and subtypes of breast cancer among U.S. women

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy

Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer

Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry